Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2016
November 2016, Vol 7, No 10
November 2016, Vol 7, No 10
Budget Impact Concerns Volume, Not Value: Prevention Is Key to Winning the War on Cancer
By
Jessica Miller
Value in Oncology
November 2016, Vol 7, No 10
Boston, MA—Are we winning the war on cancer? According to Joshua J. Ofman, MD, MSHS, Senior Vice President, Global Value, Access and Policy, Amgen, the answer is yes. Dr Ofman discussed the economics of cancer, including challenges facing insurance providers and ways to impact the rising cost of cancer care, at the War on Cancer forum hosted by
The Economist
.
Read Article
Out-of-Pocket Costs Are High for End-of-Life Care in Patients with Blood Cancers
By
Chase Doyle
Value in Oncology
November 2016, Vol 7, No 10
San Francisco, CA—For patients with hematologic malignancies, end-of-life care varies but often involves high-intensity interventions as death approaches. According to a recent analysis by Cara L. McDermott, PharmD, PhD, MSc, Senior Fellow, Fred Hutchinson Cancer Research Center, Seattle, WA, and colleagues, these interventions can come with a hefty price tag, too.
Read Article
Palliative Care Program Eases Patient Symptoms and Hospital Costs
By
Chase Doyle
Value in Oncology
November 2016, Vol 7, No 10
San Francisco, CA—In addition to improving quality of care and patient satisfaction, palliative care can also save hospitals millions of dollars, according to a study presented by lead investigator Sarina Isenberg, PhD candidate, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. The study’s final analysis showed that expanded patient access to palliative care demonstrated substantial savings to the Johns Hopkins Hospital and Health System and could lead to approximately $20 million in savings in 5 years, said Ms Isenberg at the 2016 Palliative Care in Oncology Symposium.
Read Article
The Challenges of Paying for Cancer Care Will Only Get Worse
By
Jessica Miller
Value in Oncology
November 2016, Vol 7, No 10
Boston, MA—The issues surrounding the cost of cancer care are large and looming in today’s healthcare landscape, but these problems are nothing compared to what is coming, according to Amitabh Chandra, PhD, Director of Health Policy Research, Harvard Kennedy School of Government, Cambridge, MA, who spoke at the War on Cancer forum organized by
The Economist
.
Read Article
In the Literature - November 2016
In the Literature
November 2016, Vol 7, No 10
Read Article
Immunotherapy Redefining the Treatment Strategy for Advanced Urothelial Cancer
By
Charles Bankhead
ESMO 2016
,
ESMO
November 2016, Vol 7, No 10
Copenhagen, Denmark—Two more PD-1 targeted drugs staked a claim to a role in treating advanced urothelial cancer, according to data from 2 studies that were reported at the 2016 European Society for Medical Oncology Congress.
Read Article
Niraparib Extends Progression-Free Survival in Platinum-Sensitive Ovarian Cancer
By
Phoebe Starr
Ovarian Cancer
November 2016, Vol 7, No 10
Copenhagen, Denmark—Maintenance therapy with niraparib, an oral PARP inhibitor, significantly prolonged progression-free survival (PFS) in patients with recurrent, platinum-sensitive ovarian cancer regardless of their
BRCA
mutation status and homologous recombination deficiency (HRD) status.
Read Article
Ribociclib-Letrozole Combination Potentially Practice-Changing in Advanced Breast Cancer
By
Phoebe Starr
ESMO 2016
,
ESMO
November 2016, Vol 7, No 10
Copenhagen, Denmark—The addition of the selective cyclin-dependent kinase (CDK) 4/6 inhibitor ribociclib to letrozole (Femara) significantly improved progression-free survival (PFS) in patients with hormone receptor (HR)-positive advanced breast cancer. Compared with letrozole alone, the combination of ribociclib plus letrozole improved PFS by 44%.
Read Article
The Growing Shift Toward Value-Based Drug Pricing
By
Jessica Miller
Value in Oncology
November 2016, Vol 7, No 10
Boston, MA—Drug pricing in the pharmaceutical industry came under scrutiny at the recent War on Cancer forum organized by
The Economist
. An expert panel discussed the disassociation between the actual benefits of cancer drugs and their prices.
Read Article
FDA News - November 2016
FDA Approvals, News & Updates
November 2016, Vol 7, No 10
Read Article
Page 3 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma